M

Molecure SA
WSE:MOC

Watchlist Manager
Molecure SA
WSE:MOC
Watchlist
Price: 9.42 PLN -4.56% Market Closed
Market Cap: 158.6m PLN
Have any thoughts about
Molecure SA?
Write Note

Gross Margin
Molecure SA

-444%
Current
-18%
Average
48.4%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
-444%
=
Gross Profit
-1.6m
/
Revenue
360.2k

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
PL
Molecure SA
WSE:MOC
158.6m PLN
-444%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-3%
US
Eli Lilly and Co
NYSE:LLY
756.2B USD
81%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
56%
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK
85%
US
Johnson & Johnson
NYSE:JNJ
351.2B USD
69%
US
Merck & Co Inc
NYSE:MRK
251.2B USD
77%
CH
Roche Holding AG
SIX:ROG
200.1B CHF
73%
UK
AstraZeneca PLC
LSE:AZN
161.8B GBP
82%
CH
Novartis AG
SIX:NOVN
171.5B CHF
75%
US
Pfizer Inc
NYSE:PFE
151.1B USD
71%
Country PL
Market Cap 158.6m PLN
Gross Margin
-444%
Country JP
Market Cap 776 550.9T JPY
Gross Margin
-3%
Country US
Market Cap 756.2B USD
Gross Margin
81%
Country UK
Market Cap 440.4B GBP
Gross Margin
56%
Country DK
Market Cap 2.7T DKK
Gross Margin
85%
Country US
Market Cap 351.2B USD
Gross Margin
69%
Country US
Market Cap 251.2B USD
Gross Margin
77%
Country CH
Market Cap 200.1B CHF
Gross Margin
73%
Country UK
Market Cap 161.8B GBP
Gross Margin
82%
Country CH
Market Cap 171.5B CHF
Gross Margin
75%
Country US
Market Cap 151.1B USD
Gross Margin
71%
No Stocks Found

Molecure SA
Glance View

Market Cap
158.6m PLN
Industry
Pharmaceuticals

Molecure SA engages in the discovery and development of small molecules for the treatment of unmet medical needs. The company is headquartered in Warsaw, Woj. Mazowieckie and currently employs 106 full-time employees. The company went IPO on 2018-04-19. The firm is dedicated to discovering, developing and commercializing therapeutics for neoplastic and inflammatory diseases. The firm's business model is focused on drug discovery and development, with its core strength in medicinal chemistry and preclinical biology, enhanced by scientific collaborations in specific disease areas. The firm has a platform of 3 distinct small molecule programs targeting chitinases hydrolytic enzymes with potential utility in diverse inflammatory and fibrotic diseases of high unmet medical need. Additionally, it has initiated a program focused on development of small molecule immune modulators to stop the ability of tumors to escape immune surveillance.

MOC Intrinsic Value
21.41 PLN
Undervaluation 56%
Intrinsic Value
Price
M

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
-444%
=
Gross Profit
-1.6m
/
Revenue
360.2k
What is the Gross Margin of Molecure SA?

Based on Molecure SA's most recent financial statements, the company has Gross Margin of -444%.